The pharmaceutical company Biotest plans to considerably increase its staff numbers. A new production plant for blood plasma drugs will be completed within the next two years at its headquarters in Dreieich near Frankfurt, doubling capacity, CEO Bernhard Ehmer told dpa. "Biotest is investing around 300 million euros in the project and plans to hire around 300 new employees in total,” he said. One third of them have already started work.
In 2018, the Chinese investor Creat acquired a majority stake in the company at a price of 1.3 billion euros including debt - one of the largest company acquisitions in Germany by interested parties from Asia. "With the help of Creat, all of Biotest’s loans could be paid off, creating new scope for the company," said Ehmer. The new production plant will also increase the efficiency of Biotest’s operations. "While we currently obtain three products from one liter of blood plasma, it will be five in the future".
Together with its contractual partners, Biotest processes up to 1.3 million liters of blood plasma a year. The group employs more than 1,600 people worldwide and in 2017 had a turnover of 378 million euros.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
